nach oben

Erschienen in:

29.07.2024 | Original Research: Qualitative Research

Optimizing Patient Engagement in Treatment for Opioid Use Disorder: Primary Care Team Perspectives on Influencing Factors

verfasst von: Elizabeth J. Austin, PhD, MPH, Jessica Chen, MPH, Elena Soyer, MPH, Bulat Idrisov, MD,MSc, Elsa S. Briggs, MS, Lori Ferro, MHA, Andrew J. Saxon, MD, John C. Fortney, PhD, Geoffrey M. Curran, PhD, Yavar Moghimi, MD, Brittany E. Blanchard, PhD, Emily C. Williams, PhD, MPH, Anna D. Ratzliff, MD, PhD, Monica S. Ruiz, PhD, MPH, Ulrich Koch, PhD, MSc

Erschienen in: Journal of General Internal Medicine | Ausgabe 16/2024

Einloggen, um Zugang zu erhalten

Abstract

Background

Opioid use disorder (OUD) care engagement rates in primary care (PC) settings are often low. Little is known about PC team experiences when delivering OUD treatment and potential factors that influence their capacity to engage patients in treatment. Exploring PC team experiences may inform needed supports that can optimize OUD care delivery and improve outcomes for patients with OUD.

Objective

We explored multidisciplinary PC team perspectives on barriers and facilitators to engaging patients in OUD treatment.

Design

Qualitative study using in-depth interviews.

Participants

Primary care clinical teams.

Approach

We conducted semi-structured interviews (n = 35) with PC team members involved in OUD care delivery, recruited using a combination of criterion and maximal variation sampling. Data collection and analysis were informed by existing theoretical literature about patient engagement, specifically that patient engagement is influenced by factors across individual (patient, provider), interpersonal (patient-provider), and health system domains. Interviews were professionally transcribed and doubled-coded using a coding schema based on the interview guide while allowing for emergent codes. Coding was iteratively reviewed using a constant comparison approach to identify themes and verified with participants and the full study team.

Key Results

Analysis identified five themes that impact PC team ability to engage patients effectively, including limited patient contact (e.g., phone, text) in between visits, varying levels of provider confidence to navigate OUD treatment discussions, structural factors (e.g., schedules, productivity goals) that limited provider time, the role of team-based approaches in lessening discouragement and feelings of burnout, and lack of shared organizational vision for reducing harms from OUD.

Conclusions

While the capacity of PC teams to engage patients in OUD care is influenced across multiple levels, some of the most promising opportunities may involve addressing system-level factors that limit PC team time and collaboration and promoting organizational alignment on goals for OUD treatment.

Korthuis PT, McCarty D, Weimer M, et al. Primary care–based models for the treatment of opioid use disorder: a scoping review. Ann Intern Med. 2017;166(4):268. https://doi.org/10.7326/M16-2149.

Donroe JH, Bhatraju EP, Tsui JI, Edelman EJ. Identification and management of opioid use disorder in primary care: an update. Curr Psychiatry Rep. 2020;22(5):23. https://doi.org/10.1007/s11920-020-01149-0.

Sordo L, Barrio G, Bravo MJ, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:j1550. https://doi.org/10.1136/bmj.j1550.

Larochelle MR, Bernson D, Land T, et al. Medication for opioid use disorder after nonfatal opioid overdose and association with mortality. Ann Intern Med. 2018;169(3):137-145. https://doi.org/10.7326/M17-3107.

Pytell JD, Binswanger IA. Addressing opioid use disorder in primary care: revisiting core primary care principles to confidently initiate treatment. J Gen Intern Med. Published online March 22, 2024. https://doi.org/10.1007/s11606-024-08727-5.

Barry DT, Irwin KS, Jones ES, et al. Integrating buprenorphine treatment into office-based practice: a qualitative study. J Gen Intern Med. 2009;24(2):218-225. https://doi.org/10.1007/s11606-008-0881-9.

Thomas CP, Fullerton CA, Kim M, et al. Medication-assisted treatment with buprenorphine: assessing the evidence. Psychiatr Serv. 2014;65(2):158-170. https://doi.org/10.1176/appi.ps.201300256.

Kim TW, Saitz R, Cheng DM, Winter MR, Witas J, Samet JH. Initiation and engagement in chronic disease management care for substance dependence. Drug Alcohol Depend. 2011;115(1-2):80-86. https://doi.org/10.1016/j.drugalcdep.2010.10.013.

Lagisetty P, Klasa K, Bush C, Heisler M, Chopra V, Bohnert A. Primary care models for treating opioid use disorders: What actually works? A systematic review. Hernandez-Boussard T, ed. PLOS ONE. 2017;12(10):e0186315. https://doi.org/10.1371/journal.pone.0186315.

10.

Watkins KE, Ober AJ, Lamp K, et al. Collaborative care for opioid and alcohol use disorders in primary care: the summit randomized clinical trial. JAMA Intern Med. 2017;177(10):1480. https://doi.org/10.1001/jamainternmed.2017.3947.

11.

Korthuis PT, Gregg J, Rogers WE, McCarty D, Nicolaidis C, Boverman J. Patients’ reasons for choosing office-based buprenorphine: preference for patient-centered care. J Addict Med. 2010;4(4):204-210. https://doi.org/10.1097/ADM.0b013e3181cc9610.

12.

Tofighi B, Williams AR, Chemi C, Suhail-Sindhu S, Dickson V, Lee JD. Patient barriers and facilitators to medications for opioid use disorder in primary care. Subst Use Misuse. 2019;54(14):2409-2419. https://doi.org/10.1080/10826084.2019.1653324.

13.

Haffajee RL, Andraka-Christou B, Attermann J, Cupito A, Buche J, Beck AJ. A mixed-method comparison of physician-reported beliefs about and barriers to treatment with medications for opioid use disorder. Subst Abuse Treat Prev Policy. 2020;15(1):69. https://doi.org/10.1186/s13011-020-00312-3.

14.

Austin EJ, Chen J, Briggs ES, et al. Integrating opioid use disorder treatment into primary care settings. JAMA Netw Open. 2023;6(8):e2328627. https://doi.org/10.1001/jamanetworkopen.2023.28627.

15.

Kelley AT, Wilcox J, Baylis JD, et al. Increasing access to buprenorphine for opioid use disorder in primary care: an assessment of provider incentives. J Gen Intern Med. 2023;38(9):2147-2155. https://doi.org/10.1007/s11606-022-07975-7.

16.

Saint-Pierre C, Herskovic V, Sepúlveda M. Multidisciplinary collaboration in primary care: a systematic review. Fam Pract. 2018;35(2):132-141. https://doi.org/10.1093/fampra/cmx085.

17.

Austin EJ, O’Brien QE, Ruiz MS, Ratzliff AD, Williams EC, Koch U. Patient and Provider perspectives on processes of engagement in outpatient treatment for opioid use disorder: a scoping review. Community Ment Health J. Published online September 5, 2023. https://doi.org/10.1007/s10597-023-01175-1.

18.

Archer J, Bower P, Gilbody S, et al. Collaborative care for depression and anxiety problems. Cochrane Common Mental Disorders Group, ed. Cochrane Database Syst Rev. Published online October 17, 2012. https://doi.org/10.1002/14651858.CD006525.pub2.

19.

Dahlke S, Hunter KF, Reshef Kalogirou M, Negrin K, Fox M, Wagg A. Perspectives about interprofessional collaboration and patient-centred care. Can J Aging Rev Can Vieil. 2020;39(3):443-455. https://doi.org/10.1017/S0714980819000539.

20.

Ratzliff AD, Unützer J, Katon W, Stephens KA. Integrated Care: Creating Effective Mental and Primary Health Care Teams. John Wiley & Sons, Inc.; 2016.

21.

Palinkas LA, Horwitz SM, Green CA, Wisdom JP, Duan N, Hoagwood K. Purposeful Sampling for Qualitative Data Collection and Analysis in Mixed Method Implementation Research. Adm Policy Ment Health Ment Health Serv Res. 2015;42(5):533-544. https://doi.org/10.1007/s10488-013-0528-y.

22.

Graffigna G, Vegni E. Editorial: consumer engagement in health and well-being: theoretical and empirical perspectives in patient centered medicine. Front Psychol. 2017;8. https://doi.org/10.3389/fpsyg.2017.01811.

23.

Epstein RM, Franks P, Fiscella K, et al. Measuring patient-centered communication in Patient–Physician consultations: Theoretical and practical issues. Soc Sci Med. 2005;61(7):1516-1528. https://doi.org/10.1016/j.socscimed.2005.02.001.

24.

Charmaz K. Constructing grounded theory: a practical guide through qualitative analysis. Sage; 2006.

25.

Korstjens I, Moser A. Series: Practical guidance to qualitative research. Part 4: Trustworthiness and publishing. Eur J Gen Pract. 2018;24(1):120–124. https://doi.org/10.1080/13814788.2017.1375092.

26.

Des Jarlais DC. Harm reduction in the USA: the research perspective and an archive to David Purchase. Harm Reduct J. 2017;14(1):51. https://doi.org/10.1186/s12954-017-0178-6.

27.

Soares NSA, Fernandes MA, Ribeiro HKP, Rocha D de M, Ribeiro ÍAP. Harm reduction in primary healthcare: an integrative review of care strategies. Rev Esc Enferm U P. 2020;54:e03591. https://doi.org/10.1590/S1980-220X2018051803591.

28.

Tofighi B, Grazioli F, Bereket S, Grossman E, Aphinyanaphongs Y, Lee JD. Text message reminders for improving patient appointment adherence in an office-based buprenorphine program: a feasibility study. Am J Addict. 2017;26(6):581-586. https://doi.org/10.1111/ajad.12557.

29.

Keddem S, Agha AZ, Long JA, Werner RM, Shea JA. Creating a toolkit to reduce disparities in patient engagement. Med Care. 2017;55(Suppl 2):S59-S69. https://doi.org/10.1097/MLR.0000000000000748.

30.

Kimerling R, Lewis ET, Javier SJ, Zulman DM. Opportunity or burden? A behavioral framework for patient engagement. Med Care. 2020;58(2):161-168. https://doi.org/10.1097/MLR.0000000000001240.

31.

Marchand K, Beaumont S, Westfall J, et al. Conceptualizing patient-centered care for substance use disorder treatment: findings from a systematic scoping review. Subst Abuse Treat Prev Policy. 2019;14(1):37. https://doi.org/10.1186/s13011-019-0227-0.

32.

Marchand K, Foreman J, MacDonald S, Harrison S, Schechter MT, Oviedo-Joekes E. Building healthcare provider relationships for patient-centered care: A qualitative study of the experiences of people receiving injectable opioid agonist treatment. Subst Abuse Treat Prev Policy. 2020;15(1):7. https://doi.org/10.1186/s13011-020-0253-y.

33.

Miller-Rosales C, Busch SH, Meara ER, King A, D’Aunno TA, Colla CH. Internal and environmental predictors of physician practice use of screening and medications for opioid use disorders. Med Care Res Rev MCRR. 2023;80(4):410-422. https://doi.org/10.1177/10775587231162681.

34.

Agha AZ, Werner RM, Keddem S, Huseman TL, Long JA, Shea JA. Improving patient-centered care: how clinical staff overcome barriers to patient engagement at the VHA. Med Care. 2018;56(12):1009-1017. https://doi.org/10.1097/MLR.0000000000001007.

35.

Zulman DM, O’Brien CW, Slightam C, Breland JY, Krauth D, Nevedal AL. Engaging high-need patients in intensive outpatient programs: a qualitative synthesis of engagement strategies. J Gen Intern Med. 2018;33(11):1937-1944. https://doi.org/10.1007/s11606-018-4608-2.

36.

Bridges NC, Taber R, Foulds AL, et al. Medications for opioid use disorder in rural primary care practices: Patient and provider experiences. J Subst Use Addict Treat. 2023;154:209133. https://doi.org/10.1016/j.josat.2023.209133.

37.

Hawkins EJ, Lott AMK, Malte CA, et al. Patients’ perspectives on care management services for complex substance use disorders. J Addict Dis. 2017;36(3):193-206. https://doi.org/10.1080/10550887.2017.1326654.

38.

Croff R, Hoffman K, Alanis-Hirsch K, Ford J, McCarty D, Schmidt L. Overcoming barriers to adopting and implementing pharmacotherapy: the medication research partnership. J Behav Health Serv Res. 2019;46(2):330-339. https://doi.org/10.1007/s11414-018-9616-9

39.

Hutchinson E, Catlin M, Andrilla CHA, Baldwin LM, Rosenblatt RA. Barriers to primary care physicians prescribing buprenorphine. Ann Fam Med. 2014;12(2):128-133. https://doi.org/10.1370/afm.1595.

40.

Wen H, Borders TF, Cummings JR. Trends in buprenorphine prescribing by physician specialty. Health Aff (Millwood). 2019;38(1):24-28. https://doi.org/10.1377/hlthaff.2018.05145.

41.

Santo T, Clark B, Hickman M, et al. Association of opioid agonist treatment with all-cause mortality and specific causes of death among people with opioid dependence: a systematic review and meta-analysis. JAMA Psychiatry. 2021;78(9):979. https://doi.org/10.1001/jamapsychiatry.2021.0976.

Titel: Optimizing Patient Engagement in Treatment for Opioid Use Disorder: Primary Care Team Perspectives on Influencing Factors
verfasst von: Elizabeth J. Austin, PhD, MPH
Jessica Chen, MPH
Elena Soyer, MPH
Bulat Idrisov, MD,MSc
Elsa S. Briggs, MS
Lori Ferro, MHA
Andrew J. Saxon, MD
John C. Fortney, PhD
Geoffrey M. Curran, PhD
Yavar Moghimi, MD
Brittany E. Blanchard, PhD
Emily C. Williams, PhD, MPH
Anna D. Ratzliff, MD, PhD
Monica S. Ruiz, PhD, MPH
Ulrich Koch, PhD, MSc
Publikationsdatum: 29.07.2024
Verlag: Springer International Publishing
Erschienen in: Journal of General Internal Medicine / Ausgabe 16/2024
Print ISSN: 0884-8734
Elektronische ISSN: 1525-1497
DOI: https://doi.org/10.1007/s11606-024-08963-9

Did Jesus Die of Takotsubo Cardiomyopathy? A Medical Revisiting of the Gospels

Viewpoint

Triglyceride-Glucose Index Associated with Future Renal Function Decline in the General Population

Original Research

Effective Clinical Externships for International Medical Students: A Qualitative Study

Original Research: Qualitative Research

Detained and Cognitively Impaired: Reevaluating Screening Recommendations in Carceral Settings

Viewpoint

Factors Correlated with Anticoagulation Choice in Primary Care Patients with Atrial Fibrillation and High Stroke Risk

Original Research

How a Swollen Finger Made Me Forget About the Scalpel

Healing Arts

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

ctDNA erkennt minimale Resterkrankung beim Melanom

25.04.2025
Tumormarker
Nachrichten

Die Diagnose einer minimalen Resterkrankung mithilfe zirkulierender Tumor-DNA könnte (ctDNA) auch das Management von Patientinnen und Patienten mit Melanomen im Stadium III bereichern, wie Ergebnisse einer Studie nahelegen – auch wenn die Methode noch nicht perfekt funktioniert.

Lipidtherapie im Praxisalltag: Noch viel Spielraum für Verbesserung

25.04.2025
DGK-Jahrestagung 2025
Kongressbericht

Wie steht es um die Behandlung von Dyslipidämien bei Risikopatienten mit atherosklerotischer Gefäßerkrankung in Deutschland? Eine Bestandsaufnahme dazu liefert das bei der DGK-Tagung 2025 vorgestellte Forschungsprojekt LipidSnapshot.

Lohnt sich die Karotis-Revaskularisation?

25.04.2025
Karotisstenose
Nachrichten

Die medikamentöse Therapie für Menschen mit Karotisstenosen hat sich in den vergangenen Dekaden verbessert. Braucht es also noch einen invasiven Eingriff zur Revaskularisation der Halsschlagader bei geringem bis moderatem Risiko für einen ipsilateralen Schlaganfall?

Höhere Dosis von Dexamethason senkt Überlebenschancen

25.04.2025
Zerebrale Metastasen
Nachrichten

Personen mit Hirnmetastasen, die perioperativ höhere kumulative Dosen von Dexamethason erhalten, haben eine schlechtere Prognose. Um die Ergebnisse zu verbessern, bedarf es strengerer Dosierungsschemata.

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

In diesem CME-Kurs können Sie Ihr Wissen zur EKG-Befundung anhand von zwölf Video-Tutorials auffrischen und 10 CME-Punkte sammeln.
Praxisnah, relevant und mit vielen Tipps & Tricks vom Profi.

Jetzt 10 CME-Punkte sammeln

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Optimizing Patient Engagement in Treatment for Opioid Use Disorder: Primary Care Team Perspectives on Influencing Factors